(IN BRIEF) Novartis will present 31 abstracts across its immunology portfolio at EULAR 2026 in London, highlighting new data for Cosentyx, ianalumab and rap-cel in several high-burden autoimmune diseases. Key presentations include results from REPLENISH, the largest global Phase III … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Marketing, Pharma & Biotech, Switzerland
Tagged Angelika Jahreis, AUTOGRAPH-IIM, AUTOGRAPH-SSC, autoimmune diseases, Basel, biologics, CAR-T cell therapy, CD19-directed therapy, clinical data, Cosentyx, EULAR 2026, European Alliance of Associations for Rheumatology, FUTURE 1, FUTURE 5, ianalumab, Ianalumab and Rap-Cel Data Across Rheumatology and Autoimmune Disease Research, idiopathic inflammatory myopathies, immunology, June 2026, London, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Advances Immunology Pipeline with 31 Abstracts Accepted for EULAR 2026 Congress in London, Novartis Highlights New Cosentyx, Novartis to Share Phase III and CAR-T Therapy Data Supporting Momentum in Complex Autoimmune Diseases, Phase II Study, Phase III Trial, polymyalgia rheumatica, psoriatic arthritis, rap-cel, rapcabtagene autoleucel, REPLENISH trial, rheumatology, secukinumab, Sjögren’s disease, systemic lupus erythematosus, systemic sclerosis, VAY736, YTB323
(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged ACR 2025, allergy, Angelika Jahreis, autoimmune diseases, Basel, biologics, biomarker research, CAR-T therapy, Cosentyx, Dermatology, EXPLORE44, Fortitude, HARBOR trial, ianalumab, immunology, NEPTUNUS trials, NEPTUNUS-1, NEPTUNUS-2, Novartis, Novartis Highlights Strong Immunology Pipeline with Positive Phase III Sjögren’s Results and CAR-T Data in Lupus at ACR 2025, Phase III data, psoriatic arthritis, rapcabtagene autoleucel, rheumatology, secukinumab, Sjögren’s disease, small molecules, systemic lupus erythematosus, YTB323
(IN BRIEF) Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% discount off list price for cash-paying patients. Cosentyx, a biologic approved for multiple immune-mediated … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, Switzerland
Tagged biologics, Cosentyx, direct-to-employer model, direct-to-patient platform, discount medicines, drug affordability, DTP, hidradenitis suppurativa, immune-mediated inflammatory diseases, New Direct-to-Patient Platform from Novartis Aims to Reduce Barriers and Improve Affordability, Novartis, Novartis Launches Direct-to-Patient Platform in US with Discounted Access to Cosentyx, Novartis to Provide Patients Direct Access to Lower-Priced Cosentyx Starting November 2025, NPAF, patient access, patient assistance, psoriasis, psoriatic arthritis, secukinumab, specialty medicines, US healthcare, Victor Bultó
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?